Co-Diagnostics, Inc. (CODX) stock
CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.28−0.01 (-3.78%)
Close on Nov 11, 2026Market cap $1.74MP/E –Yield –
Co-Diagnostics r&d expenses
Research and development expenses are spending on new products and technology.
Co-Diagnostics's R&D Expenses for the twelve months ending Sep 30, 2026 was $18.76M, down 0.5% year over year. For fiscal 2025 it was $19.14M, down 8.8% from the year before. The highest annual figure on record is $22.96M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.14M | -8.8% |
| FY2024 | Dec 31, 2024 | $20.98M | -8.6% |
| FY2023 | Dec 31, 2023 | $22.96M | +31.7% |
| FY2022 | Dec 31, 2022 | $17.44M | +16.5% |
| FY2021 | Dec 31, 2021 | $14.96M | +369.7% |
| FY2020 | Dec 31, 2020 | $3.19M | +132.3% |
| FY2019 | Dec 31, 2019 | $1.37M | +0.8% |
| FY2018 | Dec 31, 2018 | $1.36M | +35.7% |
| FY2017 | Dec 31, 2017 | $1.00M | +37.1% |
| FY2016 | Dec 31, 2016 | $731.47K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.57M | -20.2% |
| Q2 FY2026 | Jun 30, 2026 | $4.15M | -11.4% |
| Q1 FY2026 | Mar 31, 2026 | $5.93M | +21.8% |
| Q4 FY2025 | Dec 31, 2025 | $5.10M | +6.1% |
| Q3 FY2025 | Sep 30, 2025 | $4.48M | -8.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.69M | -16.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.87M | -14.3% |
| Q4 FY2024 | Dec 31, 2024 | $4.81M | -22.2% |
| Q3 FY2024 | Sep 30, 2024 | $4.88M | -15.7% |
| Q2 FY2024 | Jun 30, 2024 | $5.61M | -6.2% |
| Q1 FY2024 | Mar 31, 2024 | $5.68M | +13.3% |
| Q4 FY2023 | Dec 31, 2023 | $6.18M | +30.4% |
| Q3 FY2023 | Sep 30, 2023 | $5.79M | +14.9% |
| Q2 FY2023 | Jun 30, 2023 | $5.98M | +53.8% |
| Q1 FY2023 | Mar 31, 2023 | $5.01M | +33.0% |
| Q4 FY2022 | Dec 31, 2022 | $4.74M | +117.2% |
| Q3 FY2022 | Sep 30, 2022 | $5.04M | -14.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.89M | -16.7% |
| Q1 FY2022 | Mar 31, 2022 | $3.77M | +70.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.18M | +96.1% |
| Q3 FY2021 | Sep 30, 2021 | $5.89M | +539.3% |
| Q2 FY2021 | Jun 30, 2021 | $4.67M | +522.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.22M | +454.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.11M | +192.5% |
| Q3 FY2020 | Sep 30, 2020 | $921.89K | +178.5% |
| Q2 FY2020 | Jun 30, 2020 | $750.25K | +140.0% |
| Q1 FY2020 | Mar 31, 2020 | $400.02K | +15.2% |
| Q4 FY2019 | Dec 31, 2019 | $380.51K | +1.4% |
| Q3 FY2019 | Sep 30, 2019 | $331.03K | +0.2% |
| Q2 FY2019 | Jun 30, 2019 | $312.59K | -12.7% |
| Q1 FY2019 | Mar 31, 2019 | $347.31K | +16.8% |
| Q4 FY2018 | Dec 31, 2018 | $375.43K | +33.4% |
| Q3 FY2018 | Sep 30, 2018 | $330.42K | +21.4% |
| Q2 FY2018 | Jun 30, 2018 | $357.89K | +93.6% |
| Q1 FY2018 | Mar 31, 2018 | $297.42K | +11.9% |
| Q4 FY2017 | Dec 31, 2017 | $281.39K | +46.8% |
| Q3 FY2017 | Sep 30, 2017 | $272.21K | – |
| Q2 FY2017 | Jun 30, 2017 | $184.88K | – |
| Q1 FY2017 | Mar 31, 2017 | $265.69K | – |
| Q4 FY2016 | Dec 31, 2016 | $191.66K | – |
See a number that looks wrong?